ClinicalTrials.gg

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 137 studies for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating across more than 10 countries. 50 are recruiting or about to start. 108 of them are mainly about Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
51
Recruiting
36
Terminated
11
Not yet recruiting
10
Active, not recruiting
9
Status unknown
8

Phase

Phase 3
31
Phase 2
28
Phase 1
8
Phase 4
5
Early Phase 1
5

Where

United States
55
France
38
Germany
35
Italy
28
Denmark
24
Spain
23

Who develops what

Add Polyradiculoneuropathy, Chronic Inflammatory Demyelinating to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 10 companies, 13 with this as their studies’ main aim; 7 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Grifols, Takeda and argenx here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Immunoglobulins, IntravenousRecent, repeated
Evidence
  • NCT06920004 · argenx · Phase 3 · live · comparator · “IVIg” · registered Mar 2025
  • NCT06290141 · Sanofi · Phase 3 · live · background · “IVIg” · registered Feb 2024
Takeda22% of its industry studiesEU: Takeda (EMA 2006) + 2 others22 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
riliprubart☆ Track3 live phase-3 studies: NCT06290141, NCT06859099, NCT06290128Sanofi
empasiprubart☆ Track2 live phase-3 studies: NCT06920004, NCT07091630argenx
ImmunoglobulinsPhase 4 trial recorded☆ Track1 live phase-3 study: NCT06752356Kedrion S.p.A.
Immunoglobulins, IntravenousApproved: EU 2006☆ Track1 live phase-3 study: NCT07540221Grifols
Immune Globulin Subcutaneous Human☆ Track1 live phase-3 study: NCT07540221Grifols

The 5 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 9 Jul 2027 est.riliprubart · Sanofi · Phase 3 main aimstudied with Immunoglobulins, IntravenousNCT06290141 A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — primary endpoint: Percentage of participants experiencing a response · 160 enrolled
  • Sep 2027 est.empasiprubart · argenx · Phase 3 main aimvs Immunoglobulins, IntravenousNCT06920004 A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP — primary endpoint: Reduction of ≥1 point compared with baseline in aINCAT score at week 24 · 218 enrolled
  • 7 Oct 2027 est.empasiprubart · argenx · Phase 3 main aimNCT07091630 A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP — primary endpoint: Reduction of ≥1 point compared with baseline in aINCAT score at week 24 · 160 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

24studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger. 4 (11%) take children under 18. 1 (3%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.

Recruiting studies that take each age, of 36
AgeWomenMen
103 (8%)2 (6%)
1835 (97%)34 (94%)
3035 (97%)34 (94%)
4035 (97%)34 (94%)
5035 (97%)34 (94%)
6534 (94%)33 (92%)
7532 (89%)31 (86%)
8526 (72%)25 (69%)

Across all 137 studies, recruiting or not: 18% stop at 75 or younger and 7% at 65; 10% take children; 1% are for women only and 0% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 137. Browse all 137 → or search them.